Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Clinical Pathology
Published in: BMC Clinical Pathology 1/2014

Open Access 01-12-2014 | Research article

Prognostic value of the MicroRNA regulators Dicer and Drosha in non-small-cell lung cancer: co-expression of Drosha and miR-126 predicts poor survival

Authors: Kenneth Lønvik, Sveinung W Sørbye, Marit N Nilsen, Ruth H Paulssen

Published in: BMC Clinical Pathology | Issue 1/2014

Login to get access

Abstract

Background

Dicer and Drosha are important enzymes for processing microRNAs. Recent studies have exhibited possible links between expression of different miRNAs, levels of miRNA processing enzymes, and cancer prognosis. We have investigated the prognostic impact of Dicer and Drosha and their correlation with miR-126 expression in a large cohort of non-small cell lung cancer (NSCLC) patients. We aimed to find patient groups within the cohort that might have an advantage of receiving adjunctive therapies.

Methods

Dicer expression in the cytoplasm and Drosha expression in the nucleus were evaluated by manual immunohistochemistry of tissue microarrays (TMAs), including tumor tissue samples from 335 patients with resected stages I to IIIA NSCLC. In addition, in situ hybridizations of TMAs for visualization of miR-126 were performed. Kaplan–Meier analysis was performed, and the log-rank test via SPSS v.22 was used for estimating significance levels.

Results

In patients with normal performance status (ECOG = 0, n = 197), high Dicer expression entailed a significantly better prognosis than low Dicer expression (P = 0.024). Dicer had no significant prognostic value in patients with reduced performance status (ECOG = 1–2, n = 138). High Drosha expression was significantly correlated with high levels of the microRNA 126 (miR-126) (P = 0.004). Drosha/miR-126 co-expression had a significant negative impact on the disease-specific survival (DSS) rate (P < 0.001). Multivariate analyses revealed that the interaction Dicer*Histology (P = 0.049) and Drosha/miR-126 co-expression (P = 0.033) were independent prognostic factors.

Conclusions

In NSCLC patients with normal performance status, Dicer is a positive prognostic factor. The importance of Drosha as a prognostic factor in our material seems to be related to miR-126 and possibly other microRNAs.
Appendix
Available only for authorised users
Literature
1.
2.
Zhang W-C, Liu J, Xu X, Wang G: The role of microRNAs in lung cancer progression. Med Oncol. 2013, 30: 675-683.CrossRefPubMed
3.
Saito M, Schetter AJ, Mollerup S, Kohno T, Skaug V, Bowman ED, Mathé EA, Takenoshita S, Yokota J, Haugen A, Harris CC: The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. Clin Cancer Res. 2011, 17: 1875-1882. 10.1158/1078-0432.CCR-10-2961.CrossRefPubMedPubMedCentral
4.
Malleter M, Jacquot C, Rousseau B, Tomasoni C, Juge M, Pineau A, Sakanian V, Roussakis C: miRNAs, a potential target in the treatment of Non-Small-Cell Lung Carcinomas. Gene. 2012, 506: 355-359. 10.1016/j.gene.2012.06.008.CrossRefPubMed
5.
Raponi M, Dossey L, Jatkoe T, Wu X, Chen G, Fan H, Beer DG: MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res. 2009, 69: 5776-5783. 10.1158/0008-5472.CAN-09-0587.CrossRefPubMed
6.
7.
Yang J, Lan H, Huang X, Liu B, Tong Y: MicroRNA-126 inhibits tumor cell growth and its expression level correlates with poor survival in non-small cell lung cancer patients. PLoS One. 2012, 7: e42978-10.1371/journal.pone.0042978.CrossRefPubMedPubMedCentral
8.
Wang R, Wang ZX, Yang JS, Pan X, De W, Chen LB: MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14). Oncogene. 2011, 30: 2644-2658. 10.1038/onc.2010.642.CrossRefPubMed
9.
Jang JS, Jeon HS, Sun Z, Aubry MC, Tang H, Park CH, Rakhshan F, Schutz DA, Kolbert CP, Lupu R, Park JY, Harris CC, Yang P, Jen J: Increased mir-708 expression in NSCLC and its association with poor survival in lung adenocarcinoma from never smokers. Clin Cancer Res. 2012, 18: 3658-3667. 10.1158/1078-0432.CCR-11-2857.CrossRefPubMedPubMedCentral
10.
Ma L, Huang Y, Zhu W, Zhou S, Zhou J, Zeng F, Lin X, Zhang Y, Yu J: An integrated analysis of miRNA and mRNA expressions in non-small cell lung cancers. PLoS One. 2011, 6: e26502-10.1371/journal.pone.0026502.CrossRefPubMedPubMedCentral
11.
Dønnem T, Fenton CG, Lønvik K, Berg T, Eklo K, Andersen S, Stenvold H, Al-Shibli K, Al-Saad S, Bremnes R, Busund LT: MicroRNA signatures in tumor tissue related to angiogenesis in non-small cell lung cancer. PLoS One. 2012, 7: e:29671-10.1371/journal.pone.0029671.CrossRef
12.
Tan X, Qin W, Zhang L, Hang J, Li B, Zhang C, Wan J, Zhou F, Shao K, Sun Y, Wu J, Zhang X, Qui B, Li N, Shi S, Feng X, Zhao S, Wang Z, Zhao X, Chen Z, Mitchelson K, Cheng J, Guo Y, He J: A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis. Clin Cancer Res. 2011, 17: 6802-6811. 10.1158/1078-0432.CCR-11-0419.CrossRefPubMed
13.
Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F, Calabrò E, Croce CM, Pastorino U, Sozzi G: MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A. 2011, 108: 3713-3718. 10.1073/pnas.1100048108.CrossRefPubMedPubMedCentral
14.
Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL, Massagué J: Endogenous human microRNAs that suppress breast cancer metastasis. Nature. 2008, 451: 147-152. 10.1038/nature06487.CrossRefPubMedPubMedCentral
15.
Ebrahimi F, Gopalan V, Smith RA, Lam AK-Y: miR-126 in human cancers: Clinical roles and current perspectives. Exp Mol Pathol. 2014, 96: 98-107. 10.1016/j.yexmp.2013.12.004.CrossRefPubMed
16.
Cho WC, Chow AS, Au JS: Restoration of tumor-repressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation. Eur J Cancer. 2008, 45: 22197-22206.
17.
Agudo J, Ruzo A, Tung N, Salmon H, Leboeuf M, Hashimoto D, Becker C, Garrett-Sinha LA, Baccarini A, Merad M, Brown BD: The miR-216-VEGFR2 axis controls the innate response to pathogen-associated nucleic acids. Nature Immunol. 2014, 15: 54-62.CrossRef
18.
Zhu X, Li L, Hui L, Chen H, Wang X, Shen H, Xu W: miR-126 enhances the sensitivity of non-small cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor A. Acta Biochim Biophys Sin. 2012, 44: 519-526. 10.1093/abbs/gms026.CrossRefPubMed
19.
Dønnem T, Lonvik K, Eklo K, Berg T, Sorbye SW, Al-Shibli K, Al-Saad S, Andersen S, Stenvold H, Bremnes R, Busund LT: Independent and tissue-specific prognostic impact of miR-126 in non-small cell lung cancer. Cancer. 2011, 117: 3193-3200. 10.1002/cncr.25907.CrossRefPubMed
20.
Chen H, Miao R, Fan J, Han Z, Wu J, Qui G, Tang H, Peng Z: Decreased expression of mir-126 correlates with metastatic recurrence of hepatocellular carcinoma. Clin Exp Metastasis. 2013, 30: 651-658. 10.1007/s10585-013-9569-6.CrossRefPubMed
21.
Tomasetti M, Staffolani S, Nocchi L, Neuzil J, Strafella E, Manzella N, Mariotti L, Bracci M, Valentino M, Amati M, Santarelli L: Clinical significance of circulating mir-126 quantification in malignant mesothelioma patients. Clin Biochem. 2012, 45: 575-581. 10.1016/j.clinbiochem.2012.02.009.CrossRefPubMed
22.
Meister J, Schmidt MHH: miR-126 and miR-126*: New players in Cancer. Sci World J. 2010, 10: 2090-2100.CrossRef
23.
24.
Suarez Y, Fernandez-Hernando C, Yu J, Gerber SA, Harrison KD, Pober JS, Iruela-Arispe ML, Merkenschlager M, Sessa WC: Dicer-dependent endothelial microRNAs are necessary for postnatal angiogenesis. Proc Natl Acad Sci U S A. 2008, 105: 14082-14087. 10.1073/pnas.0804597105.CrossRefPubMedPubMedCentral
25.
Yang JS, Lai EC: Alternative miRNA biogenesis pathways and the interpretation of core miRNA pathway mutants. Mol Cell. 2011, 43: 892-903. 10.1016/j.molcel.2011.07.024.CrossRefPubMedPubMedCentral
26.
Macrae IJ, Zhou K, Li F, Repic A, Brooks AN, Cande WZ, Adams PD, Doudna JA: Structural basis for double-stranded RNA processing by Dicer. Science. 2006, 311: 834-838.CrossRef
27.
Lin RJ, Lin YC, Chen J, Kuo HH, Chen YY, Diccianni MB, London WB, Chang CH, Yu AL: MicroRNA signature and expression of dicer and drosha can predict prognosis and delineate risk groups in neuroblastoma. Cancer Res. 2010, 70: 7841-7850. 10.1158/0008-5472.CAN-10-0970.CrossRefPubMedPubMedCentral
28.
Karube Y, Tanaka H, Osada H, Tomida S, Tatematsu Y, Yanagisawa K, Yatabe Y, Takamizawa J, Miyoshi S, Mitsudomi T, Takahashi T: Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci. 2005, 96 (2): 111-115. 10.1111/j.1349-7006.2005.00015.x.CrossRefPubMed
29.
Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennachio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RL, Bar-Eli M, Sood AK: Dicer, Drosha and outcomes in patients with ovarian cancer. N Engl J Med. 2008, 359: 2641-2650. 10.1056/NEJMoa0803785.CrossRefPubMedPubMedCentral
30.
Grelier G, Voirin N, Ay AS, Cox DG, Chabaud S, Treilleux I, Léon-Goddard S, Rimokh R, Mikaelian I, Venoux C, Puisieux A, Lasset C, Moyret-Lalle C: Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype. Br J Cancer. 2009, 101: 673-683. 10.1038/sj.bjc.6605193.CrossRefPubMedPubMedCentral
31.
Chiosea S, Jelezcova E, Chandran U, Luo J, Mantha G, Sobol RW, Dacic S: Overexpression of Dicer in precursor lesions of lung adenocarcinoma. Cancer Res. 2007, 67: 2345-2350. 10.1158/0008-5472.CAN-06-3533.CrossRefPubMed
32.
Guo X, Liao Q, Chen P, Li X, Xiong W, Ma J, Li X, Luo Z, Tang H, Deng M, Zheng Y, Wang R, Zhang W, Li G: The microRNA-processing enzymes: Drosha and Dicer can predict prognosis of nasopharyngeal carcinoma. J Cancer Res Clin Oncol. 2012, 138: 49-56. 10.1007/s00432-011-1058-1.CrossRefPubMed
33.
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982, 5: 649-655. 10.1097/00000421-198212000-00014.CrossRefPubMed
34.
Goldstraw P: The 7th Edition of TNM in Lung Cancer: what now?. J Thorac Oncol. 2009, 4: 671-673. 10.1097/JTO.0b013e31819e7814.CrossRefPubMed
35.
World Health Organization: Histological Typing of Lung and Pleural Tumours. 1999, Geneva, Switzerland: Springer-Verlag, 3
36.
Sørbye SW, Kilvær TK, Valkow A, Dønnem T, Smeland E, Al-Shibli K, Bremnes RM, Busund LT: Prognostic impact of Jab1, p16, p21, p62, ki67 and Skp2 in soft tissue sarcomas. PLoS One. 2012, 7: e47068-10.1371/journal.pone.0047068.CrossRefPubMedPubMedCentral
37.
Nuovo GJ, Elton TS, Nana-Sinkam P, Volinia S, Croce CM, Schmittgen TD: A methodology for the combined in situ analyses of the precursor and mature forms of microRNAs and correlation with their putative targets. Nat Protoc. 2009, 4: 107-115. 10.1038/nprot.2008.215.CrossRefPubMedPubMedCentral
38.
Dønnem T, Al-Saad S, Al-Shibli K, Delghandi MP, Persson M, Nilsen MN, Busund LT, Bremnes RM: Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer. Clin Cancer Res. 2007, 13: 6649-6657. 10.1158/1078-0432.CCR-07-0414.CrossRefPubMed
39.
Davis-Dusenbery BN, Hata A: MicroRNA in cancer: the involvement of aberrant microRNA biogenesis regulatory pathways. Genes Cancer. 2011, 1: 1100-1114.CrossRef
40.
Zhu DX, Fan L, Lu RN, Fang C, Shen WY, Zou ZJ, Wang YH, Zhu HY, Miao KR, Liu P, Xu W, Li JY: Downregulated dicer expression predicts poor prognosis in chronic lymphocytic leukemia. Cancer Sci. 2012, 103: 875-881. 10.1111/j.1349-7006.2012.02234.x.CrossRefPubMed
41.
Faber C, Horst D, Hlubek F, Kirchner T: Overexpression of dicer predicts poor survival in colorectal cancer. Eur J Cancer. 2011, 47: 1414-1419. 10.1016/j.ejca.2011.01.006.CrossRefPubMed
42.
Shu G-S, Yang Z-L, Liu D-C: Immounohistochemical study of Dicer and Drosha expression in the benign and malignant lesions of gallbladder and their clinicopathological significances. Pathol Res Pract. 2012, 208: 392-397. 10.1016/j.prp.2012.05.001.CrossRefPubMed
43.
Vaksman O, Hetland TE, Trope CG, Reich R, Davidson B: Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serious ovarian carcinoma. Hum Pathol. 2012, 43: 2062-2069. 10.1016/j.humpath.2012.02.016.CrossRefPubMed
44.
Sassen S, Miska EA, Caldas C: MicroRNA – implications for cancer. Virchows Arch. 2008, 451: 1-10.CrossRef
45.
46.
Chen CC, Zhou SH: Mesenchymal stem cells overexpressing miR-126 enhance ischemic angiogenesis via the AKT/ERK-related pathway. Cardiol J. 2011, 18: 675-681. 10.5603/CJ.2011.0032.CrossRefPubMed
47.
Dønnem T, Eklo K, Berg T, Sørbye SW, Lønvik K, Al-Saad S, Al-Shibli K, Stenvold H, Bremnes RM, Busund LT: Prognostic Impact of MiR-155 in non-small Cell Lung cancer evaluated by in Situ Hybridization. J Transl Med. 2011, 9: 6-10.1186/1479-5876-9-6.CrossRefPubMedPubMedCentral
48.
Kuehlbacher A, Ubrich C, Zeiher AM, Dimmler S: Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis. Circ Res. 2011, 101: 59-69.CrossRef
49.
Palermo EI, de Campos SG, Campos M, Nogueira de Souza N, Guerreiro IDC, Carvalho AL, Marques MMC: Mechanisms and role of microRNA deregulation in cancer onset and progression. Gen Mol Biol. 2011, 34: 363-370. 10.1590/S1415-47572011000300001.CrossRef
50.
Farazi TA, Spitzer JI, Morozow P, Tusch T: miRNAs in human cancer. J Pathol. 2011, 223: 102-115. 10.1002/path.2806.CrossRefPubMed
51.
Cheloufi S, Dos Santos CO, Chong MM, Hannon GJ: A dicer-independent miRNA biogenesis pathway that requires Ago catalysis. Nature. 2010, 465: 584-589. 10.1038/nature09092.CrossRefPubMedPubMedCentral
Metadata
Title
Prognostic value of the MicroRNA regulators Dicer and Drosha in non-small-cell lung cancer: co-expression of Drosha and miR-126 predicts poor survival
Authors
Kenneth Lønvik
Sveinung W Sørbye
Marit N Nilsen
Ruth H Paulssen
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Clinical Pathology / Issue 1/2014
Electronic ISSN: 1472-6890
DOI
https://doi.org/10.1186/1472-6890-14-45

Other articles of this Issue 1/2014

BMC Clinical Pathology 1/2014 Go to the issue

Research article

Evaluation and clinical significance of the stomach age model for evaluating aging of the stomach-a multicenter study in China

Research article

Clinical chemistry profiles in injection heroin users from Coastal Region, Kenya

Research article

Implant based differences in adverse local tissue reaction in failed total hip arthroplasties: a morphological and immunohistochemical study

Case report

Giant osteoclasts in patients under bisphosphonates

Research article

High Molecular Weight (HMW): total adiponectin ratio is low in hiv-infected women receiving protease inhibitors

Research article

Galectin-1 and Galectin-3 mRNA expression in renal cell carcinoma
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits